FKBP51 Expressed by Both Normal Epithelial Cells and Adenocarcinoma of Colon Suppresses Proliferation of Colorectal Adenocarcinoma

REFERENCES

• Bierer B. E., Hollander G., Fruman D., Burakoff S. J., Cyclosporin A. and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5: 763–773
   PubMed Web of Science ®Google Scholar
• Abraham R. T., Wiederrecht G. J. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483–510
   PubMed Web of Science ®Google Scholar
• Liu J., Farmer J. D., Lane W. S., Friedman J., Weissman I., Schreiber S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807–815
   PubMed Web of Science ®Google Scholar
• O'Keefe S. J., Tamura J., Kincaid R. L., Tocci M. J., O'Neill E. A. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692–694
   PubMed Web of Science ®Google Scholar
• Baughman G., Wiederrecht G. J., Chang F., Martin M. M., Bourgeois S. Tissue distribution and abundance of human FKBP51.; an FK506-binding protein that can mediate calcineurin inhibition. Biochem Biophys Res Commun 1997; 232: 437–443
   PubMed Web of Science ®Google Scholar
• Tai P. K., Albers M. W., Chang H., Faber L. E., Schreiber S. L. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992; 256: 1315–1318
   PubMed Web of Science ®Google Scholar
• Beato M., Herrlich P., Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851–857
   PubMed Web of Science ®Google Scholar
• Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?. Cell 1998; 93: 487–490
   PubMed Web of Science ®Google Scholar
• Denny W. B., Valentine D. L., Reynolds P. D., Smith D. F., Scammell J. G. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2000; 141: 4107–4113
   PubMed Web of Science ®Google Scholar
• Giraudier S., Chagraoui H., Komura E., Barnache S., Blanchet B., LeCouedic J. P., Smith D. F., Larbret F., Taksin F., Moreau-Gachelin F., Casadevall N., Tulliez M., Hulin A., Debili N., Vainchenker W. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 2002; 100: 2932–2940
   PubMed Web of Science ®Google Scholar
• Bouwmeester T., Bauch A., Ruffner H., Angrand P. O., Bergamini G., Croughton K., Cruciat C., Eberhard D., Gagneur J., Ghidelli S., Hopf C., Huhse B., Mangano R., Michon A. M., Schirle M., Schlegl J., Schwab M., Stein M. A., Bauer A., Casari G., Drewes G., Gavin A. C., Jackson D. B., Joberty G., Neubauer G., Rick J., Kuster B., Superti-Furga G. A physical and functional map of human TNA-α NF-κ B signal transduction pathway. Nat Cell Biol 2006; 6: 97–105
   Web of Science ®Google Scholar
• Komura E., Tonetti C., Penard-Lacronique V., Chagraoui H., Lacout C., LeCouedic J. P., Rameau P., Debili N., Vainchenker W., Stephane G. Role for nuclear factor κ B pathway in transforming growth factor-β 1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005; 65: 3281–3289
   PubMed Web of Science ®Google Scholar
• Adachi Y., Taketani S., Oyaizu H., Ikebukuro K., Tokunaga R., Ikehara S. Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8. Int J Oncol 1999; 15: 1191–1196
   PubMed Web of Science ®Google Scholar
• Bock O., Neusch M., Busche G., Mengel M., Kreipe H. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. Eur J Haematol 2004; 72: 239–244
   PubMed Web of Science ®Google Scholar
• Tutton P. J., Barkla D. H. Effects of glucocorticoid hormones on cell proliferation in dimethylhydrazine-induced tumors in rat colon. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 38: 247–251
   PubMedGoogle Scholar
• Fauci A. S. Mechanisms of the immunosuppressive and anti-inflammatory effects of glucocorticosteroids. J Immunopharmacol 1978–1979; 1: 1–25
   PubMedGoogle Scholar
• Swartz S. L., Dluhy R. G. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16: 238–255
   PubMed Web of Science ®Google Scholar
• Yemelyanov A., Czwornog J., Chebotaev D., Karseladze A., Kulevitch E., Yang X., Budunova I. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2006; 26: 1885–1896
   PubMed Web of Science ®Google Scholar
• Smith R. G., Syms A. J., Nag A., Lerner S., Norris J. S. Mechanism of the glucocorticoid regulation of growth of the androgen-sensitive prostate-derived R3327H-G8-A1 tumor cell. J Biol Chem 1985; 260: 12454–12463
   PubMed Web of Science ®Google Scholar
• Cook P. W., Edwards C. P., Haraguchi T., Firestone G. L. Partial characterization of a glucocorticoid suppressible mitogenic activity secreted from a rat hepatoma cell line hypersensitivity to the antiproliferative effects of glucocorticoids. J Biol Chem 1989; 264: 14151–14158
   PubMed Web of Science ®Google Scholar
• Hatakeyama S., Sashima M., Shirasuna K., Satoh M., Suzuki A. Glucocorticoid-induced growth inhibition with enhanced expression of ductal epithelium of human salivary gland adenocarcinoma cells transplanted into athymic nude mice. Cancer 1988; 62: 716–722
   PubMed Web of Science ®Google Scholar
• Joly E., Vignon F., Rochefort H. Growth regulation of two rat adenocarcinoma cell lines by dexamethsone and progesterone. Breast Cancer Res Treat 1981; 1: 381–389
   PubMedGoogle Scholar
• Curtis R. E., Rowlings P. A., Deeg H. J., Shriner D. A., Socie G., Travis L. B., Horowitz M. M., Witherspoon R. P., Hoover R. N., Sobocinski K. A., Fraumeni J. F., Jr., Boice J. D., Jr. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904
   PubMed Web of Science ®Google Scholar